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Dog vaccination is considered an effective way of reducing Leishmania infantum infection 104 
incidence in the canine population, as well as its transmission to humans. However, the use of 105 
partially effective vaccines can have the detrimental effect of “masking” vaccinated 106 
asymptomatic carriers, capable of harbouring the parasite and transmitting it to naïve 107 
individuals. After eight years on the European market, few studies have been released on 108 
CaniLeish® vaccine safety and efficacy. The present study, a one-year randomized CaniLeish® 109 
vaccine field trial, was performed in a canine leishmaniosis endemic area and included animals 110 
selected from a native dog population (n=168). No severe adverse reactions were observed in 111 
vaccinated dogs (n=85). Cases of active L. infantum infection were detected by serological, 112 
molecular and clinical follow-up of dogs. One-year post-vaccination, no differences in number 113 
or severity of L. infantum active infections were observed between study groups (n=4 in each 114 
group). Vaccine-induced cellular immunity, assessed through interferon-γ quantification, 115 
showed significantly higher levels of this cytokine one-month post-vaccination in the vaccine 116 
group (p<0.001), but no differences were observed after nine months between trial groups 117 
(p=0.078). These results fail to support the reported CaniLeish® efficacy in the prevention of 118 
active L. infantum infection in dogs from endemic areas and naturally exposed to the parasite. 119 
 120 









1. INTRODUCTION 128 
 129 
Canine leishmaniosis (CanL) is a severe vector-borne disease which affects the domestic dog 130 
and is caused by Leishmania infantum (Gállego, 2004). The disease is endemic in the 131 
Mediterranean basin, where it is estimated to affect more than 2.5 million dogs and present an 132 
overall CanL seroprevalence of 23.2%, showing variation within micro-foci (Moreno and Alvar, 133 
2002; Gálvez et al., 2010; Franco et al., 2011; Morales-Yuste et al., 2012). It is transmitted by 134 
the bite of phlebotomine sand flies and, in the Mediterranean region, eight Phlebotomus 135 
species have been identified as vectors of the parasite (Alten et al., 2016). Detection of 136 
infected dogs is hindered by the array of possible clinical presentations, as well as by the high 137 
prevalence of asymptomatic individuals (Baneth et al., 2008). The impact of this zoonosis also 138 
extends to human health, with dogs being the main domestic reservoir for the parasite (Alvar 139 
et al., 2004). Therefore, controlling infection at the reservoir level is essential for reducing 140 
transmission amongst canids and to humans.  141 
Vaccination is seen as one of the best methods for controlling the infection (Dye, 1996) and 142 
the development of effective vaccines against both CanL and human leishmaniosis has been a 143 
goal for the scientific community. A vaccine for CanL should induce a strong and long-lasting 144 
Th1-dominated cellular immunity to control infection progression, while simultaneously 145 
reducing parasite burden in dogs to decrease their infectiousness to sand flies (Gradoni, 2015). 146 
Furthermore, it should be equally effective in protecting against infection or disease (Alvar et 147 
al., 2013). 148 
CaniLeish® (Virbac, France) was the first CanL vaccine to be licensed in Europe, in 2011 149 
(European Medicines Agency, 2011). It is a second-generation vaccine composed of purified 150 
excreted-secreted proteins (LiESP) of L. infantum and a saponin adjuvant (Moreno et al., 2012). 151 
According to pharmacovigilance data reported by Virbac in October 2015, more than 1.8 152 
million doses of CaniLeish® had been sold during the first 3.5 years of marketing in the 153 
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European Economic Area, Switzerland and Tunisia (Breton et al., 2015). However, few studies 154 
have been published since the preliminary phase II research (Moreno et al., 2012, 2014; Martin 155 
et al., 2014) and the only phase III trial performed before licensing was granted (Oliva et al., 156 
2014). After eight years on the European market, very little is known about the vaccine safety 157 
and efficacy in heterogeneous dog populations from endemic areas. Cases of CanL in 158 
vaccinated dogs have been reported (Ceccarelli et al., 2016; Gavazza et al., 2016), and the 159 
performance of the recommended pre-vaccination screening method has presented 160 
inconsistent results (Solano-Gallego et al., 2017). 161 
The present study consists of a one-year randomized controlled CaniLeish® vaccine field trial 162 
performed in a CanL Mediterranean endemic area with a heterogeneous and autochthonous 163 
canine population. Dogs of both sexes, different ages and breeds have been included. Inclusion 164 
criteria were the same as recommended by the vaccine’s manufacturer for dog vaccination 165 
and were followed for both experimental groups. The objective of this study was to provide 166 
preliminary data on CaniLeish® vaccine performance under real field conditions in a 167 
heterogeneous population of native dogs from a CanL endemic area. 168 
 169 
2. MATERIALS AND METHODS 170 
 171 
2.1. Study design and vaccination protocol 172 
The study took place in Girona province, in north-east Catalonia (Spain), an endemic area for 173 
CanL (Velez et al., 2019). At the beginning of the trial, in March 2016, 177 dogs were selected 174 
from a population of 406 dogs previously tested for the presence of anti-L. infantum 175 
antibodies by the same method described in the subsection “Serological follow-up”. All 176 
animals were kept in large packs in open-air facilities, mostly in rural and periurban areas. Dog 177 
owners were previously informed of all details of the study and signed an informed consent 178 
before the start of the trial. 179 
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Inclusion criteria for the vaccine trial followed those recommended by the CaniLeish® 180 
manufacturer and are described in Figure 1. 181 
According to the CaniLeish® vaccine manufacturer, the risk of developing L. infantum active 182 
infection is reduced by 3.6 times in vaccinated dogs (European Medicines Agency, 2011), and 183 
this was the parameter used to compare both groups. Sample size was calculated assuming a 184 
1:1 ratio between the two experimental groups, an expected 17.6% incidence of L. infantum 185 
infection in the control group (Velez and Gállego, unpublished data), 3.6 times fewer cases of 186 
active infection in the vaccine group, 10% estimated losses during one year trial, a power of 187 
0.8 and a significance level of 0.05 in a two-sided test. Final sample size of 192 dogs (96 per 188 
study group) was constrained by the number of animals available and the limitations of the 189 
research team to follow a larger group of dogs during the one-year trial. 190 
Selected animals were distributed over 12 locations, with the number of dogs per location 191 
ranging from four to 23 (Figure 2). Dogs were randomly assigned to either vaccine (n=90) or 192 
control (n=87) groups by a blinded operator using a statistical analysis software (Stata 15; 193 
StataCorp LP, College Station, TX, USA). As different locations had shown distinct infection 194 
levels, animals’ allocation to study groups was first stratified per dog kennel and then 195 
randomized. This way, an even proportion of dogs were assigned to each study group in each 196 
location, avoiding possible result bias introduced by distinct infection pressures. 197 
As recommended by the CaniLeish® vaccine manufacturer, all dogs from both groups were 198 
dewormed with a mixture of febantel, pyrantel pamoate and praziquantel prior to vaccination. 199 
From the initial selected sample of 177 individuals, only 168 dogs (85 in the vaccine group and 200 
83 in the control group) completed the vaccination course and were considered for the vaccine 201 
study (Figure 1). 202 
Both groups were followed for one year and samples were taken at different pre-determined 203 
time points, according to the study design (serological follow-up, parasitological assessment 204 
and evaluation of vaccine-induced cellular mediated immunity). Blood was collected from the 205 
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cephalic or jugular veins and transferred to EDTA tubes (for serology and clinical blood 206 
analysis) or heparin tubes (for peripheral blood mononuclear cells (PBMC) isolation and 207 
cellular mediated immunity tests). Lymph node samples were collected by fine needle 208 
aspiration and placed in 100 µL of sterile 0.9% sodium chloride solution. Plasma and lymph 209 
node samples were frozen at -40°C, and PBMC were preserved in liquid nitrogen until 210 
processing. Follow-up samples from the same dog were analysed in parallel. 211 
 212 
2.2. Clinical follow-up 213 
All dogs were clinically assessed before the beginning of the vaccine trial. This included a 214 
physical exam, complete blood count (CBC), renal and hepatic function assessment, and serum 215 
protein electrophoretogram. These results were kept as a baseline (T0) to compare with 216 
subsequent exams throughout the study. 217 
The physical exam included inspection of general body condition, hydration status, skin, hair 218 
and nail condition, mucosae, external lymph nodes and ocular lesions. Owners were asked 219 
about any recent disease, visible weight loss, anorexia, exercise intolerance, 220 
polyuria/polydipsia, vomiting or diarrhoea. Clinical assessments were repeated throughout the 221 
field trial whenever there was a suspicion of CanL, either detected by the veterinarian 222 
researchers (RV and ED) during follow-up visits or by the dog owners. At the end of the trial, a 223 
thorough physical exam was performed on all dogs. Likewise, blood analyses were repeated 224 
whenever needed to confirm a CanL case and at the end of the study for all seropositive dogs. 225 
Due to the nonspecific clinical presentation of CanL, dogs were considered symptomatic only if 226 
two or more clinical signs compatible with the disease were observed. The same criterion was 227 
followed for any detected laboratory changes. 228 
 229 
2.3. Vaccine safety assessment 230 
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After each vaccine dose, dog owners were asked to monitor their dogs and to report any 231 
adverse clinical signs observed to the researchers. Periodic revisions by the veterinarians of the 232 
team were performed. 233 
 234 
2.4. Serological follow-up 235 
A crude total L. infantum antigen in house enzyme linked immunosorbent assay (CTLA-ELISA) 236 
was used to detect IgG antibodies to L. infantum in trial dogs. The technique used has been 237 
previously described (Riera et al., 1999; Velez et al., 2019). Briefly, dog plasma samples diluted 238 
at 1:400 were incubated in titration plates (Costar®) previously coated with sonicated whole 239 
promastigotes at a protein concentration of 20 µg/mL in 0.05 M carbonate buffer at pH 9.6. 240 
Protein A peroxidase (1:30,000, Sigma®) was used as conjugate and reactions were stopped 241 
with H2SO4 3M. Results were expressed in standard units (U) compared to a calibrator control 242 
sample set arbitrarily at 100U. The cut-off was established at 24U (mean + 4 standard 243 
deviations of U of sera of dogs from non-endemic areas). 244 
Serological assessments were performed at eight time points throughout the study: before 245 
each vaccine dose (T0, Vac2, Vac3) and at one (1M), four (4M), six (6M), nine (9M) and 12 246 
months (12M) after vaccination completion. An increase of four-fold ELISA units when 247 
compared with the same dog’s basal values (ELISA units measured at T0) was considered 248 
evidence of seroconversion to L. infantum (Solano-Gallego et al., 2009). 249 
 250 
2.5. Parasitological assessment 251 
L. infantum qPCR on lymph node samples was performed in suspected cases of CanL and at the 252 
last sampling time point for seropositive dogs (12M). DNA was extracted from lymph node 253 
aspirates using the High Pure PCR Template Preparation Kit (Roche®), following the 254 
manufacturer’s instructions. A quantitative PCR was performed in all samples as described 255 
elsewhere (Martín-Ezquerra et al., 2009) with minor modifications. Briefly, qPCR mix reaction 256 
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was prepared with 5 µL of DNA, 10 µL of master mix (FastStart Universal Probe Master (ROX), 257 
Roche®), 10 µM of Leishmania primers (Leim 1 and Leim 2) and 5 µM of probe designed to 258 
target a kinetoplast DNA (kDNA) sequence, and 1 µL of H2O. Eukariotic 18S rRNA was used as 259 
endogenous control (VICTM/MGB probe, primer limited, Thermo Fisher Scientific®). 260 
Amplifications and detection were performed in an ABI7900 device (Applied Biosystems) 261 
(Genomics Service, CCITUB) and the thermal cycling profile was 50°C for 2 min, 95°C for 10 262 
min, 45 cycles at 95°C for 15 sec, and 60°C for 1 min. All samples were analysed in triplicate 263 
and positive (DNA from L. infantum MHOM/FR/95/LEM3141 strain) and negative controls 264 
were included in all qPCR reactions. Parasite quantification was performed by extrapolation 265 
from a standard curve generated with L. infantum DNA extracted from 1 x 106 parasites/mL 266 
serially diluted from 105 to 1 parasites/mL.  267 
 268 
2.6. Evaluation of vaccine-induced cellular mediated immunity (CMI) 269 
PBMC were obtained from each animal at three time points: before the first vaccine dose (T0), 270 
four weeks after the third vaccine dose (1M) and nine months after vaccination completion 271 
(9M). Only dogs with samples from the three time points were included in the CMI assessment 272 
(a total of 152 animals, 75 in the vaccine group and 77 in the control group). 273 
Heparinized whole blood samples were processed no later than 4h after collection. PBMC were 274 
isolated by centrifugation with a density gradient medium (LymphoprepTM; Stemcell 275 
Technologies), frozen in foetal bovine serum (FBS) supplemented with 10% dimethyl sulfoxide 276 
(DMSO) and stored in liquid nitrogen until processing. 277 
For the assessment of antigen-specific cytokine responses, samples from the same dog were 278 
processed together. PBMC were slowly thawed, washed and left to rest overnight at 37°C in 279 
5% CO2. The following day, cells were counted on a TC20TM Automated Cell Counter (Bio-Rad 280 
Laboratories, Inc.) and incubated in 96-well culture plates at a density of 106 cells/mL as 281 
described elsewhere (Rodríguez-Cortés et al., 2017). Briefly, PBMC were incubated with 10 282 
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µg/mL soluble L. infantum antigen (SLA), or 2.5 µg/mL concanavalin A (ConA) (positive control), 283 
or culture media (unstimulated, negative control) for a period of five days at 37°C in 5% CO2. 284 
On the fifth day, plates were centrifuged, and supernatants were collected and stored at -40°C. 285 
Interferon-γ (IFN-γ) concentration on PBMC supernatants was determined using the Canine 286 
IFN-γ DuoSet ELISA kit (R&D Systems), following manufacturer’s instructions. All samples were 287 
processed in duplicate and a standard curve was included in all plates, with a range of IFN-γ 288 
concentrations from 0 to 2000 pg/mL. Optical densities were determined at 450 nm, with 289 
wavelength correction set to 570 nm. IFN-γ concentrations were calculated using a four-290 
parameter logistic standard curve produced in GraphPad Prism® version 5.3 (GraphPad 291 
Software, San Diego, California, USA). To obtain the specific IFN-γ concentration for each 292 
sample, readings from the unstimulated cell supernatant were subtracted from the SLA-293 
stimulated cell supernatant. All plates presented a coefficient of determination (R2) above 294 
0.99. 295 
 296 
2.7. Definition of active L. infantum infection case 297 
Screening of trial dogs’ infection status was based on the results of serological tests, presence 298 
of clinical signs, and detection of CBC or plasma biochemical abnormalities compatible with 299 
CanL. Any suspicion of L. infantum infection detected by the researchers during sample 300 
collection or the dog owners throughout the trial period was further evaluated. Apart from 301 
these reported cases, and because all analyses were performed in parallel at the end of the 302 
trial, identification of CanL cases was mainly performed in April 2017. 303 
A confirmed case of active L. infantum infection was defined as: 304 
- Seroconversion to L. infantum, defined as a four-fold increase in ELISA units when compared 305 
with basal values (ELISA units measured at T0) for the same individual and, 306 
- Detection of L. infantum DNA in lymph node samples. 307 




2.8. Study endpoint 310 
Cases of CanL confirmed during the field study were submitted to treatment and follow-up or 311 
euthanasia, according to the dog owner’s decision. 312 
 313 
2.9. Statistical analysis 314 
All statistical analyses were performed using Stata 15 software (StataCorp LP, College Station, 315 
TX, USA). Continuous variables included in this study did not present a normal distribution and 316 
normality could not be achieved by data transformation. Therefore, non-parametric statistical 317 
tests were used to compare between and within groups. Comparisons between groups at each 318 
time point were performed by Mann-Whitney U test. Longitudinal comparisons within groups 319 
were performed by Wilcoxon signed-rank test. Statistical significance of difference in 320 
proportions between groups was tested by the Pearson Chi-square test. Graphs were built in 321 
GraphPad Prism® 5.3 (GraphPad Software, San Diego, California, USA). 322 
 323 
3. RESULTS 324 
 325 
3.1. Characteristics of the study population 326 
The majority of the study dog population was composed of hunting dogs (87.1% of the vaccine 327 
group and 83.9% of the control group), but breeding (8.9% of the total dog population), racing 328 
(6.5%) or pet dogs (0.6%) were also represented; no statistically significant differences in dog 329 
purpose between trial groups were observed (χ2=3.66, p=0.3). Crossbred dogs represented 330 
55.3% of the vaccine group and 45.8% of the control group (χ2=1.52, p=0.218), and 55.3% and 331 
65.1% of the vaccine and control groups, respectively, were males (χ2=1.67, p=0.196). Mean 332 
dog age in the vaccine group was 3.3 years (SD=2.9) and 3.4 years in the control group 333 




3.2. Vaccine safety 336 
No severe adverse reactions were observed in vaccinated dogs. One case of transient anorexia 337 
and apathy following first vaccine dose administration was reported, which was not observed 338 
again in the same animal following the second or third vaccination dose. No other adverse 339 
reactions were reported. 340 
 341 
3.3. Humoral and molecular detection of L. infantum 342 
In April 2017 (12M post-vaccination), 35 animals were seropositive for L. infantum and were 343 
further tested by qPCR on lymph node samples (21 in the vaccine group and 14 in the control 344 
group). From these, 19 (54.3%) presented a positive qPCR result [nine vaccine (42.9%) and ten 345 
control (71.4%)], with parasite loads ranging from 0.39 to 1.24x107 parasites/mL (Table 1). No 346 
statistically significant differences were detected in the incidence of positive results (χ2=2.76, 347 
p=0.096) or in lymph node parasite loads (z=1.31, p=0.1903) between groups. 348 
 349 
3.4. Vaccine-induced CMI 350 
At the pre-vaccination sampling point, 28.3% of the trial dogs (43/152) presented L. infantum-351 
specific IFN-γ production (20 dogs in the vaccine group and 23 in the control group). 352 
Measurable IFN-γ concentrations at this time point ranged from 2.50 to 7317.25 pg/mL.  353 
Levels of IFN-γ in vaccine and control groups throughout the study are presented in Figure 3. 354 
Median IFN-γ levels for the control group were equal to zero (range: 0 to 7317.25 pg/mL) in 355 
the three sampling points tested and no differences were detected in this group between time 356 
points (p>0.05). Dogs in the vaccine group showed a statistically significant increase in IFN-γ 357 
levels 1M after vaccination completion (median=38.95 pg/mL; range: 0 to 5136.58 pg/mL) 358 
compared to pre-vaccination (T0) levels (z=-6.624, p<0.001). At 9M after vaccination, IFN-γ 359 
levels had dropped considerably (median=12.74 pg/mL; range: 0 to 6235.92 pg/mL), being 360 
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significantly lower when compared to the 1M time point (z=3.149, p=0.002), but still 361 
significantly higher than pre-vaccination levels (z=-2.931, p=0.003). Differences between 362 
vaccine and control groups were only significant at the 1M time point (z=-3.297, p=0.001). No 363 
statistically significant differences in IFN-γ levels were detected between groups at the pre-364 
vaccination (T0) (p=0.730) or 9M time points (p=0.078). 365 
The levels of IFN-γ presented by healthy and diseased dogs are presented as supplementary 366 
material (Figure S1). IFN-γ levels tended to be lower in diseased dogs from both groups, 367 
although no statistically significant differences were observed. 368 
 369 
3.5. Clinical assessment of trial dogs 370 
At the end of the vaccine trial, 87.6% of dogs (127/145) were considered asymptomatic for 371 
CanL [62 dogs in the vaccine group (87.3%) and 65 in the control group (87.8%)]. The 372 
remaining 18 animals (12.4%) showed two or more clinical signs compatible with CanL [nine in 373 
the vaccine group (12.7%) and nine in the control group (12.2%)]. These were mainly 374 
characterized by localized or multifocal lymphadenomegaly (detected in 100% of symptomatic 375 
dogs) and pale mucous membranes (50% of symptomatic dogs). Other observed clinical signs 376 
were dermatological lesions (38.9%), poor body condition (27.8%) and ocular alterations 377 
(22.2%). 378 
Laboratory exams after T0 were only performed in dogs suspected of CanL during the trial and 379 
in seropositive dogs at the end of the trial. At 12M, 37.1% of the analysed dogs (13/35) were 380 
considered healthy (none or one laboratory change compatible with CanL) (11 in the vaccine 381 
group and two in the control group), while 42.9% presented two or three analytical alterations 382 
(seven dogs in the vaccine group and eight dogs in the control group), and 20% showed four to 383 
six laboratory abnormalities (three vaccine and four control).  384 
Table 1 describes clinical and laboratory alterations found in confirmed cases of active L. 385 




3.6. Confirmed cases of active L. infantum infection in the vaccine and control groups 388 
Dogs were evaluated one year after vaccination completion for seropositivity against L. 389 
infantum. From these, 35 dogs showed positive anti-L. infantum antibody levels (21 in the 390 
vaccine (29.6%) and 14 in the control (18.9%) groups) in one of the two post-transmission 391 
season serological assessments (January and April 2017). These 35 dogs were further assessed 392 
by L. infantum DNA detection in lymph node samples by qPCR and clinical-laboratory 393 
evaluation. Only dogs that met the parameters previously defined for L. infantum active 394 
infection (seroconversion to L. infantum and parasite DNA detection in lymph node aspirate) 395 
were considered to be confirmed infection cases. From these, four cases were observed in 396 
both vaccinated (5.6%; 4/71) and control dogs (5.4%; 4/74). Results showed no difference in 397 
the development of active L. infantum infection between the two study groups (Table 1). 398 
 399 
4. DISCUSSION 400 
 401 
The objective of the present study, a multi-site randomized vaccine field trial, was to obtain a 402 
preliminary and independent evaluation of CaniLeish® vaccine efficacy in field conditions in a 403 
native heterogeneous population of dogs living in a L. infantum endemic region. From the 177 404 
dogs initially enrolled in the vaccine study, 168 completed the vaccination phase (95%) [85 405 
dogs in the vaccine group (94.4%) and 83 in the control group (95.4%)]. Similarly, the expected 406 
loss to follow-up in this study was 10%, based on preliminary assessments performed on the 407 
same dog population. However, at the end of the study, 18% of the initial dog sample had 408 
been lost, mainly due to deaths related to hunting activities and animal movement to other 409 
dog kennels. 410 
Canine seropositivity to L. infantum at the end of the trial was detected in 75% (9/12) of the 411 
trial locations, demonstrating the presence of infection in most dog kennels. Accordingly, a 412 
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homogeneous vector presence has been shown in the study area together with a high 413 
incidence of dog exposure to sand fly saliva (Velez et al., 2018).  414 
The studied outcome was active L. infantum infection and not clinical CanL as detection of 415 
CanL clinical cases was not expected due to the short duration of the present clinical trial, 416 
which included only one L. infantum transmission season. Nevertheless, CanL clinical cases 417 
were identified during this field trial in both study groups. The mean period between infection 418 
and development of clinical disease was reported to be seven months, ranging from three to 419 
14 months (Oliva et al., 2006), but it can extend to years in resistant dogs (Baneth et al., 2008).  420 
CaniLeish® vaccine proved to be safe in the dog population studied. Apart from one single case 421 
of transient apathy and anorexia, no other adverse effects were reported by dog owners or 422 
observed by the researchers, which is in accordance with previous vaccine safety reports 423 
(Breton et al., 2015; Marino et al., 2017). However, it should be noted that the study 424 
population was mainly composed of robust crossbred or purebred hunting dogs weighing 425 
between 15 and 25 kg, which may be less likely to show discomfort than dogs of smaller 426 
breeds. In a questionnaire-based survey of veterinary practitioners working in Girona region, 427 
82% of vaccine appliers reported adverse reactions, ranging from the most commonly 428 
observed local swelling and pain, to cases of anaphylactic shock (Lladró et al., 2017). However, 429 
as also pointed out by the study authors, the attribution of these adverse effects to vaccine 430 
administration was based on veterinarians’ criteria and confirmation of the cause of clinical 431 
signs may not have been pursued in all occasions.  432 
In the present study, a CTLA-ELISA that measures the humoral immune response to L. infantum 433 
was used as a diagnostic test for infection. Quantitative serological tests are considered 434 
reliable indicators of active infection and good predictors of the onset of clinical signs (Oliva et 435 
al., 2006). Seroconversion has been defined as a four-fold increase in sequential samples from 436 
the same dog (Paltrinieri et al., 2010) or a three-fold increase in the cut-off value of a well-437 
standardized diagnostic test (Solano-Gallego et al., 2009). In endemic areas, the median time 438 
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between the establishment of progressive infection and seroconversion was estimated to be 439 
10.5 months (ranging from four to 22 months) (Oliva et al., 2006). The dynamic of antibody 440 
levels during this study corresponded to the one described in previous studies for IFAT (Martin 441 
et al., 2014; Oliva et al., 2014), and indicates that vaccine-induced antibodies can interfere 442 
with L. infantum screening by a CTLA-ELISA (Velez et al., 2020).  443 
Molecular detection of the parasite was performed in lymph node samples at the end of the 444 
trial to confirm the diagnosis of active L. infantum infection in seropositive dogs. Although the 445 
levels of seropositivity considered for infection diagnosis in the study were very conservative 446 
and clear indicators of progressive infection, the detection of the parasite in a target organ 447 
validated the serological results. In addition, the detection of parasite DNA in lymph nodes in 448 
the absence of seroconversion would not have been considered as a definitive confirmation of 449 
infection.  450 
IFN-γ is considered a high-quality biomarker of immunogenicity and protection against 451 
Leishmania infection (Reis et al., 2010). It is considered the key cytokine involved in the 452 
activation of macrophages and the killing of intracellular L. infantum amastigotes, in 453 
collaboration with other immune mechanisms (Carrillo and Moreno, 2009). High levels of IFN-γ 454 
are associated with host resistance to L. infantum infection (Chamizo et al., 2005; Solano-455 
Gallego et al., 2016) and this has been used as a marker of response to CanL therapy (Manna 456 
et al., 2008; Martínez-Orellana et al., 2017), including in the evaluation of new drugs (Corpas-457 
López et al., 2018). It has also been quantified as a marker of protection in previous vaccine 458 
studies, both for CaniLeish® (Moreno et al., 2012, 2014; Martin et al., 2014), and for other 459 
vaccines (Fernandes et al., 2008; De Lima et al., 2010). According to the results obtained in this 460 
study, IFN-γ levels tended to be lower in diseased dogs (presented as supplementary material 461 
S1). Although not statistically significant, possibly due to the reduced number of infected dogs, 462 
the observed difference between healthy and diseased animals supports a protective effect of 463 
IFN-γ. Apart from providing an indication of vaccine-induced CMI, the quantification of IFN-γ in 464 
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this study also allowed the assessment of previous exposure to L. infantum in the trial 465 
population. According to the results obtained in the pre-vaccination assessment, almost 30% 466 
of dogs presented a measurable IFN-γ response when exposed to SLA, which indicates L. 467 
infantum recognition and possible pre-established natural immunity to the parasite. Some 468 
degree of resistance to infection is expected in canine populations from endemic areas 469 
(Baneth et al., 2008), although its impact may be difficult to quantify and account for when 470 
setting a field trial. 471 
Levels of IFN-γ measured in the vaccine group one month after vaccination completion showed 472 
a marked increase when compared to the pre-vaccination time point or to parallel levels in the 473 
control group, in accordance with the results obtained in a previous CaniLeish® study (Moreno 474 
et al., 2012). This corresponds to the point when vaccine-induced immunity should be 475 
established (European Medicines Agency, 2011), and illustrates the stimulation of CMI 476 
response in vaccinated dogs. IFN-γ concentrations were measured again 9M after vaccination, 477 
showing a marked decrease in this cytokine levels in the vaccine group. Results from previous 478 
CaniLeish® studies, performed with a sample of 20 beagle dogs under laboratory conditions, 479 
have shown a statistically significant difference in the proportion of IFN-γ producing cells 480 
between vaccine and control dogs at 6M post-vaccination (Moreno et al., 2014), but no 481 
difference between groups was reported at one year post-vaccination (Martin et al., 2014; 482 
Moreno et al., 2014). In these studies, the 9M post-vaccination time point was not assessed. 483 
Unlike the two studies mentioned, the present study was performed in field conditions and 484 
animals were naturally exposed to one L. infantum transmission season, therefore exposure-485 
induced IFN-γ may have interfered with vaccine-induced cytokine levels. Nevertheless, three 486 
months after the end of the transmission season, vaccinated dogs did not show differences in 487 
IFN-γ production when compared to the control group. A short-lived vaccine induced CMI 488 
which fails to be protective during the whole period of expected vaccine coverage could 489 
explain the lack of difference in detected active L. infantum infection cases between vaccine 490 
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and control groups observed at the end of this study. Nevertheless, care should be taken in the 491 
over-interpretation of a single parameter as it is known that IFN-γ is only part of a complex 492 
network of regulatory and counter-regulatory interactions involving multiple cells and 493 
cytokines (Reis et al., 2010; Hosein et al., 2017). Further studies on the immune response 494 
developed by trial dogs would be needed to fully characterize vaccine induced CMI. 495 
The combined information provided by humoral and molecular assays allowed the 496 
identification of eight active L. infantum infection cases. Two dogs, one in each trial group, 497 
were identified as diseased during the study. The remaining six (three in each group) were 498 
detected at the end of the trial. According to previous vaccine studies in natural conditions, 499 
where a continued parasite challenge is present, it is unlikely that these animals may revert to 500 
a negative state (Oliva et al., 2014). The CaniLeish® vaccine reports an efficacy of 68.4% in the 501 
prevention of clinical signs of CanL and a protection level, defined as the percentage of 502 
vaccinated animals which do not develop clinical signs, of 92.7%. These results were obtained 503 
during the only vaccine pre-licensing field study in a homogeneous population of 90 naïve 504 
beagle dogs, five to 7.5 months old (Oliva et al., 2014). In the study by Oliva et al. (2014), four 505 
cases of active Leishmania infection were recorded at 12M post-vaccination, one in the vaccine 506 
group (2.4%) and three in the control group (7.7%); all these dogs progressed to symptomatic 507 
active infection in the following months. In the present trial, no differences in number or 508 
severity of active infection cases were detected between vaccine and control groups one-year 509 
post-vaccination. Although the reduced number of observed positive cases demands caution in 510 
the interpretation of the results of this study, these are supported by a recent field study, 511 
which compared the efficacy of CaniLeish® vaccine and two insecticide dog collars in the 512 
prevention of CanL (Brianti el al., 2016). After one year, although different protection efficacies 513 
could be determined for each insecticide collar, no difference was detected in the number of 514 
CanL cases between CaniLeish® vaccinated dogs and the control group. Again, the total 515 
21 
 
number of CanL cases detected in the aforementioned trial presented by Brianti et al. was low, 516 
which may have impaired the detection of a difference between groups. 517 
The ultimate step to assess the efficacy of a vaccine against CanL is a phase III field trial with 518 
native canine populations from endemic areas, where vaccinated and control dogs are 519 
exposed to natural infection by sand fly bites (Reis et al., 2010). However, in contrast to 520 
laboratory experimental challenge, natural infection depends on many variable factors related 521 
to the canine host, the vector and the parasite. According to Solano-Gallego et al. (2009), only 522 
an estimated one third of dogs living in CanL endemic areas will be susceptible to infection 523 
during the course of their lives. This implies that, at the time of enrolment for a vaccine field 524 
trial, a high proportion of animals testing negative for L. infantum are already resistant to the 525 
parasite and will be “useless” in terms of vaccine effect assessment. Another important factor 526 
of variability in field trials is vector related. Sand fly populations are highly influenced by biotic 527 
and abiotic factors (Barón et al., 2011; Hartemink et al., 2011; Ballart et al., 2014), which 528 
change annually. Some of these factors, such as temperature, are also known to influence L. 529 
infantum development inside the vector (Rioux et al., 1985). Likewise, it is impossible to 530 
guarantee the success of natural parasite transmission in a given area and year. For these 531 
reasons, field trials with privately owned dogs are challenging and their success difficult to 532 
predict. Nevertheless, they represent the closest situation to a “real life” scenario, allowing for 533 
a more realistic assessment of vaccine performance. 534 
 535 
5. CONCLUSION 536 
 537 
The CaniLeish® vaccine proved to be safe in the studied population of dogs from a CanL 538 
endemic area. However, no difference in number or severity of active L. infantum infection 539 
cases between vaccine and control groups was observed during the first-year post-vaccination. 540 
The vaccine induced L. infantum-specific IFN-γ production one month after vaccination 541 
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completion, but levels were not maintained at nine months post-vaccination. The results 542 
obtained in this study do not support the previously reported CaniLeish® efficacy in the 543 
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FIGURE LEGENDS: 758 
 759 
Figure 1. Flow chart of pre-vaccination procedures and vaccine field trial. 760 
 761 
Figure 2. Map of Girona province. Field trial locations are marked in black circles; the number 762 
of study dogs per location (n) is presented. 763 
 764 
Figure 3. Median and interquartile ranges of IFN-γ levels observed in the vaccine and control 765 
groups at three time points: before vaccination (T0), one month after vaccination completion 766 
(1M) and nine months after vaccination completion (9M). (a) Within group comparison with 767 
T0; (b) within group comparison with 1M; (c) between group comparison. (**) indicates 768 
statistical significance of p≤0.01; (***) indicates statistical significance of p≤0.001. 769 
 770 
Supplementary figure S1. Levels of IFN-γ observed in infected and non-infected dogs at three 771 
time points: before vaccination (T0), one month after vaccination completion (1M) and nine 772 
months after vaccination completion (9M). Panel A: includes all dogs from both vaccine and 773 
control groups. Panel B: includes only dogs from vaccine group. 774 




